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Abstract: 
Background: There is a growing interest in vortioxetine in major depressive disorder (MDD). 
Objectives: This meta-analysis aimed to assess the efficacy and safety of  10 mg/day (mg/d) vortioxetine compared to placebo 
for MDD in adult.
Methods: Eight randomly controlled trials (RCTs) about the treatment of  10 mg/d vortioxetine in adult patients with MDD 
were identified and 2354 patients were included in meta-analysis. 
Results: According to the results, 10 mg/d vortioxetine showed significant differences in response rates (OR=1.88, 95% 
CI=1.40-2.53, P<0.0001), remission rates (OR=1.54, 95% CI=1.27-1.86, P<0.00001), change from baseline in Montgomery-As-
berg Depression Rating Scale (MADRS) total score (SMD=-3.50, 95%CI=-4.83 to -2.17, P<0.00001), clinical global Impres-
sion-Global Improvement (CGI-I) total score (SMD=-3.40, 95% CI=-4.69 to -2.11, P<0.00001), and change from baseline in 
Sheehan Disability Scale (SDS) total score (SMD=-2.09, 95% CI=-2.64 to -1.55, P<0.00001). But 10 mg/d vortioxetine was 
easier induced nausea (OR=4.18, 95% CI=3.21-5.44, P<0.00001) and constipation (OR=1.88, 95% CI=1.14 to 3.09, P=0.01).
Conclusion: 10 mg/d vortioxetine was more effective, but easily induced nausea and constipation when compared to placebo 
for MDD in adult. 
Keywords: Vortioxetine, major depressive disorder, meta-analysis.
DOI: https://dx.doi.org/10.4314/ahs.v19i1.48
Cite as: Zheng J, Wang Z, E L. The efficacy and safety of  10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a me-
ta-analysis. Afri Health Sci. 2019;19(1). 1716-1726. https://dx.doi. org/10.4314/ ahs. v19i1.48 
Corresponding author: 
Zhaoyu Wang, 
Guangdong Provincial Key Laboratory 
of  Biotechnology Candidate 
Drug Research, School of  Biosciences and 




Depressive disorder is one of  serious diseases plaguing 
mankind1,2. It is a chronic and recurring disease with con-
siderable morbidity and mortality in general population3. 
The World Health Organization found that over 350 
million people suffered from depression over the whole 
world and the disease was spread in all age people. De-
pression impair the quality of  life and daily functioning 
of  patients with major depressive disorder (MDD), and 
at its most severe, depression can lead to suicide. It esti-
mated that over 1 million patients end their life due to the 
depression every year4. Depression is not only the leading 
cause of  disability worldwide, but also the chief  factor to 
lead the world burden of  disease.
Vortioxetine is a novel antidepressant that was approved 
by the U.S. Food and Drug Administration (FDA) recent-
ly for the treatment of  MDD5. It was considered that the 
activity of  vortioxetine was shown through two mecha-
nism: the direct modulation of  receptor activity and the 
inhibition of  the serotonin reuptake6,7. Some vitro stud-
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ies indicated that vortioxetine was the receptor antago-
nist of  5-HT3 and 5-HT7 receptors, the partial agonist 
of  5-HT1B receptor, the agonist of  5-HT1A receptor, 
and the 5-HT transporter inhibitor8. In vivo non-clin-
ic studies, vortioxetine can enhance the level of  5-HT, 
noradrenaline, dopamine, acetylcholine and histamine in 
specific areas of  the brain was demonstrated9. However, 
the effective dosage of  vortioxetine for the treatment of  
MDD was uncertain until now. 
The recommended dosage of  vortioxetine was 5-20 mg/
day (mg/d) at present10. Several articles have report-
ed the efficacy of  vortioxetine in the dosage of  5 mg/
d11-16,10 mg/d13,15-20, and 20 mg/d18,20,21. And there were a 
few articles about the dosage of  2.5 mg/d11,15,17, which 
was not recommended currently. However, these articles 
showed inconsistent results. So some people have con-
ducted meta-analysis to assess the efficacy and safety of  
different dosage vortioxetine. Jie Fu et al.22 have assessed 
the difference of  efficacy and safety between 5 mg/d vor-
tioxetine and placebo through a meta-analysis, thus they 
demonstrated that 5 mg/d vortioxetine was more effec-
tive but more easier to lead nausea for the treatment of  
MDD. And it was indicated that 20 mg/d vortioxetine 
also more effective than placebo by a meta-analysis con-
ducted by Masoud Behzadifar23. In this article, we have 
assessed the efficacy and safety of  10 mg/d vortioxetine 
in adult MDD for the current meta-analysis based on the 
newest available data in published studies.
       
Material and methods 
Sources of  data
In this systematic and meta-analysis, we searched Pubmed, 
PsycINFO,  Sciencedirect, Google Scholar, Embase, 
Ebsco, Cochrane Central Register of  Controlled Trials 
and Clinical-Trials.gov using the terms “vortioxetine”, 
“Lu AA21004” or “Brintellix” vs “depression”, “mood 
disorder” or “depressive disorder”. All databases were 
searched from the available date of  inception until the 
latest issue (February 2016). The search was limited to 
individual randomized controlled trials (RCTs) and had 
no language restriction. 
 
Selection criteria 
Studies were selected for analysis if  they met the follow-
ing criterias: (1) Eligibility was limited to RCTs of  MDD; 
(2) Clinical trials testing the efficacy of  vortioxetine for 
the short term treatment of  MDD; (3) the dosage of  vor-
tioxetine was 10 mg/d; (4) Studies compared the efficacy 
and safety of  vortioxetine to placebo for the treatment 
of  MDD; (5) Patients in the RCT were diagnosed with 
MDD according to the Diagnostic and Statistical Manual 
of  Mental Disorders, 4th edition, text revised (DSM-IV-
TR) and were required to have a Montgomery-Asberg 
Depression Rating Scale (MADRS)24 total score≥26, and 
aged from 18 to 75 years old.
 
Data extraction
The data (study design, quality criteria, participant charac-
teristics, intervention details, outcome measures, baseline 
and posttreatment results) were independently extracted 
by two authors (Jiahuan Zheng and Zhaoyu Wang). Any 
discrepant data between the two reviewers were resolved 
by consensus, or, if  necessary, by a third reviewer. We se-
lected the following indicators as the outcomes: response, 
remission, change from baseline in MADRS total score at 
week 8, clinical global Impression-Global Improvement 
(CGI-I) total score at week 8, change from baseline in 
Sheehan Disability Scale (SDS) total score at week 8, and 
AEs. Response was defined as ≥50% decrease from base-
line MADRS total scores, and the remission was defined 
as the MADRS total scores<1024. If  the studies compared 
different doses vortioxetine to placebo, only the 10 mg/d 
and placebo doses were included in our meta-analysis. 
 
Quality assessment
The study quality was assessed using Jadad five-point 
scores for RCTs25. The key domains were: randomization 
(0-2 points), blindness (0-2 points), and dropouts (0-1 
point). If  the study was described as randomized such 
as “randomly”, “random”, and “randomization”, adding 
one point to the study; an additional point would be given 
if  the specific item of  randomization was described and 
it was appropriate. At last, a point was deducted if  the 
study did not mention the randomization. This method 
was also applied to blinding. If  there had a description 
of  withdraws or dropouts in the study, adding one point, 
otherwise, adding zero. The maximum point of  a study is 
five. Studies with a total score of  3 or more were regarded 
as high study quality.
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Statistical analysis
The effect and safety of  10 mg/d vortioxetine on MDD 
were calculated as differences between the treatment 
group and the placebo control group using Review Man-
ager 5.1 meta-analysis software. Heterogeneity26 would be 
evaluated using the Higgins I2 test before effect size (ES) 
pooled. when the studies in the group were similar enough 
(P>0.10), the fixed-effects model was used to assess the 
results. While the studies were not similar (P<0.10 or 
I2>50%), the results were assess though random-effects 
model. The overall effect was tested using a Z-score with 
significance set at P<0.05. Odd ratio (OR) and 95% con-
fidence intervals (CIs) were calculated for dichotomous 
data, while standardized mean differences (SMD) and 
the 95% confidence intervals (CIs) were calculated for 
continuous data. A sensitivity analysis was performed to 
study robustness of  the meta-analysis consequence and 
explore the potential sources when high heterogeneity 
was found. Publication bias was not assessed here since 
the number of  included studies was small. 
Results 
Study selection process
The process of  study selection was shown as the flow 
chart in Fig. 1. Firstly, 1813 articles were identified from 
Pubmed, PsycINFO, Sciencedirect, Google Scholar, Em-
base, Ebsco, Cochrane Central Register of  Controlled 
Trials and Clinical-Trial. gov. And then 1717 articles were 
removed by reviewing their abstracts and headlines. 
Secondly, 67 articles were excluded since they had dupli-
cated citations with others; 10 articles were excluded since 
that they were the same trials with different publication 
to others; 6 articles were not included since they were not 
placebo controlled trials; 1 article was eliminated since it 
was not a RCT; 2 articles were not included since they 
were not acute phase studies; 2 articles were finally ex-
cluded due to the participants in the trials. At last, 8 RCTs 
included 2354 patients were met the inclusion criteria and 
were included in the meta-analysis19,15,16,13,20,18,27,28. Fig.1 
 
 
Fig 1. Search flow: trial identification and selection process 
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Study characteristics
All eight included studies19,15,16,13,20,18,27,28 were randomized, 
double-blind, parallel-group, and placebo-controlled 
trails. Patients in all eight studies were older than 17 
years and younger than 75 years. Patients in the vortiox-
etine group received more than one dosage vortioxetine, 
whereas patients in the placebo group received a placebo 
treatment. Homogeneity is a very important variable in 
the depression level of  patients.Hence, only those pa-
tients who have a MADRS score≥26 can be included in 
the RCTs. The baseline MADRS score was at least 26, in-
dicating that patients included in vortioxetine trials were 
all in the depressed symptom. Details of  eight studies 
were shown in table 1. Quality assessment of  the includ-
ed RCTs was presented in Table 2 and Jadad scores were 
shown here as well.
Table 1 Characteristic of the included studies 
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Table 2 Jadad score of the included studies 
  
Study Randomization  Blindness  Dropouts  Scores  
Atul et al,  
2015 1 2 1 4 
David et al,  
2012 2 1 1 4 
Enric et al, 
2012 1 1 1 3 
Neven et al,  
2012 1 2 1 4 
Paula et al,  
2015 1 2 1 4 
Roger S. et al, 








1 1 1 3 
Efficacy
A total eight RCTs with 2354 patients, 1172 in the 10 mg/
day vortioxetine group and 1182 patients in the placebo 
group were included in our meta-analysis. The OR for re-
sponse rate with 10 mg/d compared to placebo was 1.88 
(95% CI=1.40 to 2.53, P<0.0001, Z=4.17, I2=66%) (Fig. 
2). Meanwhile, there was a statistically significant differ-
ence for remission rate with an OR=1.54 (95% CI=1.27 
to 1.86, P<0.00001, Z=4.45, I2=22%) (Fig. 3). The stan-
dard mean different ratio (SMD) for MADRS change 
was -3.50 (95% CI=-4.83 to -2.17, P<0.00001, Z=5.17, 
I2=99%) (Fig. 4), and the SMD was -3.40 (95% CI=-4.69 
to -2.11, P<0.00001, Z=5.16, I2=99%) for CGI-I (Fig. 
5), and for SDS change, the SMD was -2.09 (95% CI=-
2.64 to -1.55, P<0.00001, Z=7.50, I2=93%) (Fig. 6).
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Fig.2 Odds ratios (ORs) and 95% confidence intervals (CIs) of the individual studies  
and the pooled data for all included studies comparing the response rate  







Fig.3 Odds ratios (ORs) and 95%confidence intervals (CIs) of the individual studies  
and the pooled data for all included studies comparing the remission rate  
between 10 mg/day vortioxetine and placebo 
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Fig. 4 Standardized mean differences (SMDs) and 95 % confidence intervals (CIs) of  
the individual studies and the pooled data comparing the change from  







Fig. 5 Standardized mean differences (SMDs) and 95 % confidence intervals (CIs)  
of the individual studies and the pooled data comparing the CGI-I score  







Fig. 6 Standardized mean differences (SMDs) and 95 % confidence intervals (CIs) of  
the six included studies and the pooled data comparing the change from baseline  
SDS score between 10 mg/day vortioxetine and placebo 
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Safety 
The common adverse effects related to vortioxetine treat-
ment were nausea, headache, diarrhoea, dizziness, naso-
pharyngitis, constipation, fatigue, and dry mouth. It was 
showed that 10 mg/d vortioxetine had extremely signif-
icant difference on nausea when compared to placebo 
(OR=4.18, 95% CI=3.21 to 5.44, P<0.00001, Z=10.62 
I2=0%) in results. And the OR was 1.88 (95% CI=1.14 
to 3.09, P=0.01, Z=2.49, I2=1%) for constipation. But 
the others were not observed difference between 10 
mg/d vortioxetine and placebo (headache OR=0.94, 
95% CI=0.73 to 1.21, P=0.64, Z=0.46, I2=0%; naso-
pharyngitis OR=0.81, 95% CI=0.58 to 1.15, P=0.24, 
Z=1.18, I2=0%; diarrhoea OR=1.07, 95% CI=0.75 
to 1.52, P=0.71, Z=0.37, I2=1%; dizziness OR=0.95, 
95% CI=0.63 to 1.44, P=0.83, Z=0.22, I2=43%; fa-
tigue OR=1.13, 95% CI=0.68 to 1.90, P=0.63, Z=0.48, 
I2=0%; and dry mouth OR=1.11, 95% CI=0.75 to 1.64, 
P=0.61, Z=0.51, I2=46%) (Fig. 7).
 
 
Fig. 7 Odds ratio (OR) and 95% confidence intervals (CIs) of nausea, headache, nasopharyngitis, 
diarrhoea, dizziness, constipation, fatigue and dry mouth AEs in the included studies 
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Sensitivity analysis
A sensitivity analysis did not find that the pooled effects 
of  change from baseline MADRS score, CGI-I score and 
change from baseline SDS score were significantly influ-
enced when we excluded any study one by one. 
 
Discussion
The efficacy and safety of  vortioxetine 10 mg/d verse 
placebo for treatment of  MDD was examined in our 
study including eight RCTs. The present meta-analysis 
showed that the response and remission of  vortioxetine 
10 mg/d was greater than placebo. The superior antide-
pressant efficacy of  vortioxetine 10 mg/d  compared to 
placebo were demonstrated in terms of  mean change of  
MADRS score, GCI-I mean score, mean change of  SDS 
score. A sensitivity analysis did not influence the results 
when we ruled out any study one by one.  
MADRS24 is a scale to measure overall severity of  depres-
sive symptoms (such as apparent sadness, reported sad-
ness, inner tension). Higher scores indicate greater sever-
ity of  symptoms. A decrease is equal or more than 50% 
in the MADRS total score from baseline is defined as re-
sponse while remission is defined as a participant with a 
MADRS total score less than or equal to 10. Our results 
showed that patients in vortioxetine group had a higher 
response rate when compared to placebo group, and sim-
ilarly, the remission rate was also higher in 10 mg/d vor-
tioxetine group than in placebo group. All these results 
indicated that patients treated with 10 mg/d vortioxetine 
could receive a better efficacy than patients treated with 
placebo. Further more, the MADRS score and SDS score 
were declined more serious and the CGI-I score was low-
er in the 10 mg/d vortioxetine group. The SDS29 com-
prises self-rated items designed to measure impairment 
and the CGI-I30 assesses the participant's improvement. 
A decrease in the SDS total score indicates improvement, 
and the lower CGI-I score who gets, the much improved 
situation he will have. Thus our results demonstrated the 
improvement was shown in the 10 mg/d vortioxetine 
group.  
The high heterogeneity (>75%) was found in the pooled 
trials of  the change from baseline MADRS score, CGI-I 
score, and change from baseline SDS score, though we 
designed the inclusion criteria when we selected proper 
studies. The sensitively analysis did not influence the re-
sults which indicate that there was no single study can 
decide the pooled ES and the high heterogeneity. Many 
factors could contribute to the high heterogeneity such as 
the difference of  patients’ region and age. And the dura-
tion of  patients taking drugs in different trial was differ-
ence, which may also a contribution to the heterogeneity. 
The gender of  patients was also a key factor to influence 
the improvement of  depression since that women were 
easier to experience depression than men31. It also con-
tributed to the heterogeneity that the data of  women and 
men were not separated to analyze respectively in our me-
ta-analysis. 
The incidence rate of  nausea and constipation in the 10 
mg/d vortioxetine group were significantly higher than 
placebo group in our analysis, which mean 10 mg/d vor-
tioxetine would easily lead patients to feel nausea or con-
stipation. Jie Fu et al.19 and Masoud Behzadifar et al.32 
have ever reported that vortioxetine was easier in leading 
patients experience nausea. It may be a reason that pa-
tients refuse to take vortioxetine.
 
Conclusion 
The current meta-analysis of  published RCTs indicated 
that 10 mg/d vortioxetine was more effective than place-
bo for the treatment of  adult major depressive disorder. 
But the patients in 10 mg/d vortioxetine group can easier 
to experience nausea and constipation.
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